Title (en)

MEDICAMENTS AND METHODS FOR TREATING AIDS AND ARC EMPLOYING ANTI-CARBOHYDRATE ANTIBODIES AND CARBOHYDRATE ANTIGENS

Publication

EP 0512023 A4 19930630 (EN)

Application

EP 91903499 A 19910124

Priority

US 47066690 A 19900126

Abstract (en)

[origin: WO9111199A1] A medicament for inhibiting or slowing the progression of acquired immune deficiency syndrome (AIDS) and AIDS related complex (ARC) comprising a pharmaceutically effective amount of one or more antibodies selected from the group consisting of anti-Le<Y>, anti-AI and anti-sialyl-Tn, and a pharmaceutically acceptable carrier, diluent or excipient. A method for inhibiting or slowing the progression of AIDS and ARC comprising administering to a subject having AIDS or ARC a medicament comprising a pharmaceutically effective amount of one or more antibodies selected from the group consisting of anti-Le<Y>, anti-AI and anti-sialyl-Tn and a pharmaceutically acceptable carrier, diluent or excipient. A vaccine against AIDS and ARC, comprising an immunologically effective amount of one or more antigens selected from the group consisting of Le<Y>, AI and sialyl-Tn, and a pharmaceutically acceptable carrier, diluent or excipient. A method of actively immunizing against AIDS and ARC, comprising administering to a subject a medicament comprising an immunologically effective amount of one or more antigens selected from the group consisting of Le<Y>, AI and sialyl-Tn, and a pharmaceutically acceptable carrier, diluent or excipient.

IPC 1-7

A61K 39/395; A61K 39/00

IPC 8 full level

A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61P 31/12 (2006.01); A61P 31/18 (2006.01); C07K 14/00 (2006.01); C07K 14/705 (2006.01); C07K 16/00 (2006.01); C07K 16/18 (2006.01); C07K 16/30 (2006.01); C07K 16/34 (2006.01); C12N 5/10 (2006.01); C12N 5/20 (2006.01); C12N 15/02 (2006.01); C12P 21/08 (2006.01); A61K 38/00 (2006.01); C12R 1/91 (2006.01)

CPC (source: EP US)

A61P 31/12 (2018.01 - EP); A61P 31/18 (2018.01 - EP); C07K 14/705 (2013.01 - EP); C07K 16/18 (2013.01 - EP); C07K 16/30 (2013.01 - EP); C07K 16/34 (2013.01 - EP); A61K 38/00 (2013.01 - EP); A61K 39/00 (2013.01 - EP US)

Citation (search report)

• [X] EP 0304663 A1 19890301 - JAPAN IMMUNO RES LAB [JP]
• [A] WO 8908711 A1 19890921 - BIOMEMBRANE INST [US]
• [X] THE JOURNAL OF IMMUNOLOGY vol. 142, no. 9, 1 May 1989, BALTIMORE MD, US pages 3070 - 3075 S. PINCUS ET AL. 'Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates.'
• [A] CANCER RESEARCH vol. 48, no. 8, 15 April 1988, PHILADELPHIA PA, US pages 2214 - 2220 T. KJELDSEN ET AL. 'Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope.'
• [XP] THE JOURNAL OF VIROLOGY vol. 64, no. 6, June 1990, BALTIMORE MD, US pages 2833 - 2840 J. HANSEN ET AL. 'Inhibition of human immunodeficiency virus (HIV) infection in vitro by anti-carbohydrate monoclonal antibodies: Peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization.'
• See also references of WO 9111199A1

Designated contracting state (EPC)

AT BE CH DE DK ES FR GB GR IT LI LU NL SE

DOCDB simple family (publication)

WO 9111199 A1 19910808; AT E134649 T1 19960315; AU 653141 B2 19940922; AU 6961491 A 19910821; CA 2073459 A1 19910727; CA 2074512 A1 19910727; DE 69025629 D1 19960404; DE 69025629 T2 19960704; EP 0511967 A1 19921111; EP 0511967 B1 19960228; EP 0512023 A1 19921111; EP 0512023 A4 19930630; ES 2082962 T3 19960401; FI 923348 A0 19920723; FI 923348 A 19920723; JP H05506565 A 19930930; JP H05506843 A 19931007; NO 922941 D0 19920724; NO 922941 L 19920917; WO 9111528 A1 19910808

DOCDB simple family (application)

US 9100373 W 19910124; AT 91900749 T 19901213; AU 6961491 A 19901213; CA 2073459 A 19910124; CA 2074512 A 19901213; DE 69025629 T 19901213; EP 9002161 W 19901213; EP 91900749 A 19901213; EP 91903499 A 19910124; ES 91900749 T 19901213; FI 923348 A 19920723; JP 50122991 A 19901213; JP 50360191 A 19910124; NO 922941 A 19920724